MAPT and supranuclear palsy, progressive, 1: For instance, off-target signal in the basal ganglia may impact the quantitation of basal ganglia signal elevations in non-Alzheimer’s disease neurodegenerative conditions such as PSP or CBD, which is likely to already be affected by the lower affinity of flortaucipir for non-Alzheimer’s disease tau.